Takeda has announced a long-term collaboration with the Indonesian government to strengthen the country’s plasma collection and manufacturing capabilities, with the aim of improving access to plasma-derived medicinal products (PDMPs) for patients in Indonesia and supporting global supplies.
The partnership involves Indonesia’s Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM, and the Coordinating Ministry for Economic Affairs. As part of the agreement, Indonesia’s Ministry of Health has granted Takeda a fractionation license, allowing the company to move forward with plans to develop the country’s plasma ecosystem.
The initiative is considered the first collaboration of its kind in the Association of Southeast Asian Nations (ASEAN) and is designed to support the sustainable collection of high-quality human plasma and the production of plasma-derived medicines.
Plasma-derived medicinal products are therapies made from proteins found in human blood plasma. They are used to treat a wide range of serious and rare diseases, including immune disorders, bleeding disorders, and certain neurological conditions. Demand for these medicines continues to increase worldwide, but many countries, including those in Southeast Asia, still face shortages and limited access.
Indonesia hopes the collaboration will strengthen its healthcare system while reducing dependence on imported plasma therapies.
Indonesia’s Minister of Health, Budi Gunadi Sadikin, said the initiative reflects the country’s commitment to building stronger healthcare capabilities and ensuring sustainable access to important and innovative treatments.
He said working with experienced international partners such as Takeda will help Indonesia develop a more resilient healthcare system that is better prepared to meet future medical needs.
Takeda said it will invest up to US$30 million during the first phase of the project, which will include a two-year pilot program to establish plasma donation centers across Indonesia.
The donation centers will allow the company and Indonesian health authorities to evaluate the feasibility of building a larger national plasma collection network in the future.
According to Takeda, the centers will follow international quality and regulatory standards while using the company’s experience from its global plasma donation operations.
The company said the project is expected to create new employment opportunities, including highly skilled jobs for healthcare professionals, laboratory technicians and other specialists. The initiative will also include workforce training and knowledge transfer to help develop local expertise in plasma collection and processing.
In addition to plasma collection, Takeda plans to study the feasibility of building a state-of-the-art plasma-derived therapy manufacturing facility in Indonesia.
If developed, the manufacturing plant could supply plasma-derived medicines not only for Indonesian patients but also for other countries, helping position Indonesia as an important regional center for advanced biopharmaceutical manufacturing.
Ramy Riad, President of Plasma-Derived Therapies at Takeda, said the collaboration demonstrates the company’s commitment to improving access to plasma-derived medicines while supporting stronger healthcare systems.
He noted that Takeda introduced its first plasma-derived medicinal products in Indonesia earlier this year and is now expanding its investment by developing local plasma infrastructure. According to Riad, the partnership aims to improve patient care, create skilled jobs, strengthen long-term medicine supplies and support Indonesia’s healthcare goals.
Indonesia’s Minister of Investment and Downstream Industry and Chairman of BKPM, Rosan P. Roeslani, described the project as the type of long-term strategic investment the country wants to attract.
He said the partnership will provide benefits beyond financial investment by encouraging technology transfer, workforce development and job creation. He added that the collaboration supports Indonesia’s ambition to become a regional hub for life sciences and biopharmaceutical manufacturing.
Takeda also highlighted the growing global need for plasma-derived medicines. The company said many countries continue to face challenges because of limited plasma supplies, underdiagnosis of treatable conditions and low public awareness about plasma donation.
By investing in plasma collection, workforce training and public awareness, the collaboration aims to strengthen both Indonesia’s healthcare system and the broader global plasma supply network.
The first plasma donation center is expected to open in 2027 and will become part of Takeda’s BioLife plasma donation network. Until a local manufacturing facility is established, plasma collected in Indonesia will be processed through Takeda’s existing global manufacturing network, with the company stating that Indonesia’s domestic needs for plasma-derived medicines will remain a priority in accordance with national regulations.